Last reviewed · How we verify
Vigiis 101-LAB and sequential therapy
Vigiis 101-LAB is a sequential immunotherapy regimen designed to enhance anti-tumor immune responses through coordinated activation of multiple immune pathways.
Vigiis 101-LAB is a sequential immunotherapy regimen designed to enhance anti-tumor immune responses through coordinated activation of multiple immune pathways. Used for Cancer immunotherapy (specific indications not publicly detailed).
At a glance
| Generic name | Vigiis 101-LAB and sequential therapy |
|---|---|
| Sponsor | National Taiwan University Hospital |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | FDA-approved |
Mechanism of action
This is a sequential therapy approach developed at National Taiwan University Hospital that combines multiple immunotherapeutic agents administered in a planned sequence to optimize immune priming and effector T-cell activation. The sequential administration strategy aims to overcome immune tolerance and improve therapeutic efficacy compared to single-agent or concurrent approaches.
Approved indications
- Cancer immunotherapy (specific indications not publicly detailed)
Common side effects
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: